SCHEMBL23879682

SCHEMBL23879682

CC(C)CN(C)C(=O)[C@H]1CCOC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.45
HSD17B10 Q99714 7/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 2/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 2/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.34
ACKR3 P25106 1/20 0.32
MLYCD O95822 1/20 0.32
ACACB O00763 1/20 0.32
PDE4D Q08499 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21649536 1.00 PIK3CD (0.45) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL24344800 1.00 PIK3CD (0.45) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL15343542 0.81 HSD17B10 (0.39) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL23469838 0.81 HSD17B10 (0.39) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL771983 0.79 HSD17B10 (0.39) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL21649512 0.79 HSD17B10 (0.39) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL23432880 0.78 HSD17B10 (0.38) HSD17B10SMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL13036147 0.77 HSD17B10 (0.42) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1
SCHEMBL23717362 0.77 RIPK1 (0.42) PIK3CDHSD17B10KDM4EACKR3
SCHEMBL12989181 0.77 HSD17B10 (0.38) PIK3CDHSD17B10SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136320-B2 Fused ring derivative used as FGFR4 inhibitor JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136320-B2 Fused ring derivative used as FGFR4 inhibitor FGFR4, FGFR1, FGFR3 PIK3CD 765/4885HSD17B10 493/4885SMN1; SMN2 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.